Literature DB >> 25595186

WWOX, the chromosomal fragile site FRA16D spanning gene: its role in metabolism and contribution to cancer.

Robert I Richards1, Amanda Choo2, Cheng Shoou Lee2, Sonia Dayan2, Louise O'Keefe2.   

Abstract

The WWOX gene spans the common chromosomal fragile site FRA16D that is located within a massive (780 kb) intron. The WWOX gene is very long, at 1.1 Mb, which may contribute to the very low abundance of the full-length 1.4 kb mRNA. Alternative splicing also accounts for a variety of aberrant transcripts, most of which are devoid of C-terminal sequences required for WWOX to act as an oxidoreductase. The mouse WWOX gene also spans a chromosomal fragile site implying some sort of functional relationship that confers a selective advantage. The encoded protein domains of WWOX are conserved through evolution (between humans and Drosophila melanogaster) and include WW domains, an NAD -binding site, short-chain dehydrogenase/reductase enzyme and nuclear compartmentalization signals. This homology has enabled functional analyses in D. melanogaster that demonstrate roles for WWOX in reactive oxygen species regulation and metabolism. Indeed the human WWOX gene is also responsive to altered metabolism. Cancer cells typically exhibit altered metabolism (Warburg effect). Many cancers exhibit FRA16D DNA instability that results in aberrant WWOX expression and is associated with poor prognosis for these cancers. It is therefore thought that aberrant WWOX expression contributes to the altered metabolism in cancer. In addition, others have found that a specific (low-expression) allele of WWOX genotype contributes to cancer predisposition.
© 2015 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  Chromosomal fragile site; FRA16D; altered metabolism; oxidoreductase

Mesh:

Substances:

Year:  2015        PMID: 25595186      PMCID: PMC4935231          DOI: 10.1177/1535370214565990

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  45 in total

Review 1.  Mechanisms of common fragile site instability.

Authors:  Thomas W Glover; Martin F Arlt; Anne M Casper; Sandra G Durkin
Journal:  Hum Mol Genet       Date:  2005-10-15       Impact factor: 6.150

2.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.

Authors:  A K Bednarek; K J Laflin; R L Daniel; Q Liao; K A Hawkins; C M Aldaz
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

3.  The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype.

Authors:  Xiao Wang; Lan Chao; Guohui Ma; Liansheng Chen; Yixiu Zang; Jingzhong Sun
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-18       Impact factor: 4.553

4.  WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function.

Authors:  Rami I Aqeilan; Valentina Donati; Alexey Palamarchuk; Francesco Trapasso; Mohamed Kaou; Yuri Pekarsky; Marius Sudol; Carlo M Croce
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

5.  Constitutive fragile sites and cancer.

Authors:  J J Yunis; A L Soreng
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

6.  Association of Wwox with ErbB4 in breast cancer.

Authors:  Rami I Aqeilan; Valentina Donati; Eugenio Gaudio; Milena S Nicoloso; Maria Sundvall; Anna Korhonen; Johan Lundin; Jorma Isola; Marius Sudol; Heikki Joensuu; Carlo M Croce; Klaus Elenius
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

7.  Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review.

Authors:  Paolo E Porporato; Suveera Dhup; Rajesh K Dadhich; Tamara Copetti; Pierre Sonveaux
Journal:  Front Pharmacol       Date:  2011-08-25       Impact factor: 5.810

8.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

9.  The supposed tumor suppressor gene WWOX is mutated in an early lethal microcephaly syndrome with epilepsy, growth retardation and retinal degeneration.

Authors:  Ghada Abdel-Salam; Michaela Thoenes; Hanan H Afifi; Friederike Körber; Daniel Swan; Hanno Jörn Bolz
Journal:  Orphanet J Rare Dis       Date:  2014-01-23       Impact factor: 4.123

Review 10.  Medium- and short-chain dehydrogenase/reductase gene and protein families : the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes.

Authors:  K L Kavanagh; H Jörnvall; B Persson; U Oppermann
Journal:  Cell Mol Life Sci       Date:  2008-12       Impact factor: 9.261

View more
  15 in total

Review 1.  Decoding the link between WWOX and p53 in aggressive breast cancer.

Authors:  Suhaib K Abdeen; Rami I Aqeilan
Journal:  Cell Cycle       Date:  2019-05-16       Impact factor: 4.534

Review 2.  Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells.

Authors:  Muhannad Abu-Remaileh; Emma Joy-Dodson; Ora Schueler-Furman; Rami I Aqeilan
Journal:  J Biol Chem       Date:  2015-10-23       Impact factor: 5.157

Review 3.  HYAL-2-WWOX-SMAD4 Signaling in Cell Death and Anticancer Response.

Authors:  Li-Jin Hsu; Ming-Fu Chiang; Chun-I Sze; Wan-Pei Su; Ye Vone Yap; I-Ting Lee; Hsiang-Ling Kuo; Nan-Shan Chang
Journal:  Front Cell Dev Biol       Date:  2016-12-06

4.  Hyaluronan activates Hyal-2/WWOX/Smad4 signaling and causes bubbling cell death when the signaling complex is overexpressed.

Authors:  Li-Jin Hsu; Qunying Hong; Shur-Tzu Chen; Hsiang-Lin Kuo; Lori Schultz; John Heath; Sing-Ru Lin; Ming-Hui Lee; Dong-Zhang Li; Zih-Ling Li; Hui-Ching Cheng; Gerard Armand; Nan-Shan Chang
Journal:  Oncotarget       Date:  2017-03-21

5.  Down-regulated HSDL2 expression suppresses cell proliferation and promotes apoptosis in papillary thyroid carcinoma.

Authors:  Jing Zeng; Xiao Ma; Jinjing Wang; Ran Liu; Yun Shao; Yanwei Hou; Zhiyuan Li; Yi Fang
Journal:  Biosci Rep       Date:  2019-06-04       Impact factor: 3.840

6.  Tumor Suppressor WWOX Contributes to the Elimination of Tumorigenic Cells in Drosophila melanogaster.

Authors:  Louise V O'Keefe; Cheng Shoou Lee; Amanda Choo; Robert I Richards
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

7.  Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function.

Authors:  Sara Del Mare; Rami I Aqeilan
Journal:  Sci Rep       Date:  2015-08-10       Impact factor: 4.379

8.  WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia.

Authors:  Muhannad Abu-Remaileh; Abed Khalaileh; Eli Pikarsky; Rami I Aqeilan
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

Review 9.  Genomic instability and cancer: lessons from Drosophila.

Authors:  Stephan U Gerlach; Héctor Herranz
Journal:  Open Biol       Date:  2020-06-03       Impact factor: 6.411

Review 10.  Modeling WWOX Loss of Function in vivo: What Have We Learned?

Authors:  Mayur Tanna; Rami I Aqeilan
Journal:  Front Oncol       Date:  2018-10-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.